Second Sight Medical Products- Warrants (14/03/2024) Long Term Debt

The latest long-term debt for EYESW is $16M as of June 2026. That compares with $17M in the prior-year period — down 7.3% year over year. Investors often review this figure alongside Second Sight Medical Products- Warrants (14/03/2024)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, EYESW's long-term debt moved from $17M to $16M — a 7.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Second Sight Medical Products- Warrants (14/03/2024)'s operating scale or balance-sheet position.

A long-term debt figure of $16M for EYESW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting EYESW's long-term debt ($16M), review year-over-year change from $17M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Second Sight Medical Products- Warrants (14/03/2024)'s long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.